

HHS Public Access

Engineering (Beijing). Author manuscript; available in PMC 2024 January 25.

Published in final edited form as:

Author manuscript

Engineering (Beijing). 2020 May; 6(5): 541-545. doi:10.1016/j.eng.2019.07.027.

Putative Mode of Action of the Monoterpenoids Linalool, Methyl Eugenol, Estragole, and Citronellal on Ligand-Gated Ion Channels

Amy S. Li^{a,c}, Akimasa lijima^a, Junhao Huang^{a,†}, Qing X. Li^b, Yongli Chen^{a,*}

^aCollege of Natural and Computational Sciences, Hawaii Pacific University, Kaneohe, HI 96744, USA

^bDepartment of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, HI 96822, USA

^cDepartment of Internal Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA

Abstract

Essential oil has been used as sedatives, anticonvulsants, and local anesthetics in traditional medical remedies; as preservatives for food, fruit, vegetable, and grain storage; and as biopesticides for food production. Linalool (LL), along with a few other major components such as methyl eugenol (ME), estragole (EG), and citronellal, are the active chemicals in many essential oils such as basil oil. Basil oil and the aforementioned monoterpenoids are potent against insect pests. However, the molecular mechanism of action of these chemical constituents is not well understood. It is well-known that the γ -aminobutyric acid type A receptors (GABA_ARs) and nicotinic acetylcholine receptor (nAChR) are primary molecular targets of the synthetic insecticides used in the market today. Furthermore, the GABA_AR-targeted therapeutics have been used in clinics for many decades, including barbiturates and benzodiazepines, to name just a few. In this research, we studied the electrophysiological effects of LL, ME, EG, and citronellal on GABAAR and nAChR to further understand their versatility as therapeutic agents in traditional remedies and as insecticides. Our results revealed that LL inhibits both GABAAR and nAChR, which may explain its insecticidal activity. LL is a concentration-dependent, noncompetitive inhibitor on GABA_AR, as the half-maximal effective concentration (EC_{50}) values of γ -aminobutyric acid (GABA) for the rat $\alpha 1\beta 3\gamma 2L$ GABA_AR were not affected by LL: $(36.2 \pm 7.9) \mu \text{mol}\cdot\text{L}^{-1}$ and $(36.1 \pm 23.8) \mu \text{mol}\cdot\text{L}^{-1}$ in the absence and presence of 5 mmol·L⁻¹ LL, respectively. The half-maximal inhibitory concentration (IC₅₀) of LL on GABA_AR was approximately 3.2 mmol· L^{-1} . Considering that multiple monoterpenoids are found within the same essential oil, it is likely that LL has a synergistic effect with ME, which has been previously

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Corresponding author. ychen@hpu.edu (Y. Chen).

[†]Current address: Guangdong Provincial Key Laboratory of Sports and Health Promotion, Scientific Research Center, Guangzhou Sport University, Guangzhou 510500, China.

Compliance with ethics guidelines

Amy S. Li, Akimasa Iijima, Junhao Huang, Qing X. Li, and Yongli Chen declare that they have no conflicts of interest or financial conflicts to disclose.

characterized as both a $GABA_AR$ agonist and a positive allosteric modulator, and with other monoterpenoids, which offers a possible explanation for the sedative and anticonvulsant effects and the insecticidal activities of LL.

Keywords

Essential oil; γ -Aminobutyric acid type A receptor; Linalool; Monoterpenoid; Nicotinic acetylcholine receptor

1. Introduction

Linalool (LL), methyl eugenol (ME), estragole (EG), and citronellal are major compounds found in many plant essential oils such as those extracted from basil, lavender, and lemongrass. Essential oils have been used as sedatives, anticonvulsants, antimicrobials, anxiolytics, and local anesthetics in traditional medical remedies [1,2]. In modern applications, the aforementioned compounds are found in aromatherapy products [3], flavoring agents [4], fragrance products, insecticides [5,6], and various household cleaning agents [7]. Many of the chemical constituents of basil oil display anticonvulsant activities in experimental animal models [8]. Basil oil has also shown anti-hyperalgesic effects in fibromyalgia murine models [9]. In addition, LL (a major constituent in many essential oils, particularly basil oil) is effective in the pentylenetetrazol, picrotoxin, and maximal electroshock seizure models [10,11], and has exhibited sedative effects in murine models [12]. Previous studies have found that these properties are related to the γ aminobutyric acid (GABA)ergic, cholinergic, dopaminergic, glutaminergic, serotoninergic, and parasympathetic systems [6,8,13–16]. However, the molecular mechanisms of action of those chemical constituents, including LL, ME, EG, and citronellal are not well understood.

The γ -aminobutyric acid type A receptors (GABA_ARs) are the primary inhibitory neurotransmitter receptors in the central nervous system (CNS). The GABA_ARs belong to the cys-loop ligand-gated ion channel family, which also includes the nicotinic acetylcholine receptor (nAChR), an excitatory neurotransmitter receptor. Many studies have proven that GABA_ARs play essential roles in epilepsy and many other neurodegenerative disorders. A number of clinically prescribed drugs, such as the benzodiazepine family, potentiate GABA_AR inhibitory functions. Interestingly, the potentiation potency of some anticonvulsants on GABA_AR does not correlate well with the drug's anticonvulsive efficacy, and some of them inhibit the Nav1.2 voltage-gated sodium ion (Na⁺) channels [17,18]. Furthermore, lamotrigine, an anticonvulsant, was recently reported to inhibit the nAChR [19], in addition to blocking the voltage-gated Na⁺ channels [20]. Therefore, since basil oil has been used as sedative, anticonvulsant, bio-pesticide, and food preservative [5,21], here we studied the electrophysiological effects of the major monoterpenoid components of basil oil (Fig. 1) on the nAChR and GABA_AR in order to further elucidate the molecular mechanism of action of those monoterpenoids.

2. Materials and methods

2.1. Chemicals

All chemicals, including GABA, (–)-LL, ME, EG, (*R*)-citronellal ((*R*)-C), (*S*)-citronellal ((*S*)-C), and pentylenetetrazole (PTZ), were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA) unless otherwise specified.

2.2. Cell culture

The WSS-1 cell line (ATCC; CRL-2029TM) and the KX α 3 β 4R2 cell line (a generous gift from Dr. Yingxian Xiao, Georgetown University), which stably express the rat α 1 β 3 γ 2L GABA_AR [22,23] and the rat α 3 β 4 nAChR subtype [24], respectively, were maintained in GlutaMAXTM medium (Thermo Fisher Scientific; Waltham, MA, USA) supplemented with 10% fetal bovine serum, 0.4 mg·mL⁻¹ G-418, 100 units·mL⁻¹ penicillin, and 0.1 mg·mL⁻¹ streptomycin at 37 °C and 5% CO₂. Subcultures were performed twice a week at approximately 75%–90% confluency using a 1:5 dilution ratio split. The cells were used between 24 and 72 h after incubation in tissue culture plates for whole-cell current recordings.

2.3. Whole-cell current recordings

Whole-cell currents were amplified using a computer-controlled patch clamp amplifier (EPC 10 USB) (HEKA Elektronik; Holliston, MA, USA) with a built-in digitizer (LIH 8+8) (HEKA Elektronik; Holliston, MA, USA) and recorded using the data-acquisition software PatchMaster (HEKAElektronik; Holliston, MA, USA). Recording pipettes of 2–3 M Ω were pulled from borosilicate glass capillaries (World Precision Instruments; Sarasota, FL, USA) using a Narishige PC-10 vertical pipette puller (Narishige International USA, Inc.; Amityville, NY, USA). The intracellular electrode buffer consisted of 140 mmol·L⁻¹ CsCl, 10 mmol·L⁻¹ ethylene glycol tetraacetic acid (EGTA), 2 mmol·L⁻¹ MgCl₂, 10 mmol·L⁻¹ tetraethylammonium chloride (TEA-Cl), and 10 mmol·L⁻¹ 4-(2-hy droxyethyl)-1-piperazineethanesulfonic acid (HEPES), adjusted to pH = 7.4 with CsOH. The TEA-Cl was not included in the intracellular electrode buffer was composed of 145 mmol·L⁻¹ NaCl, 5 mmol·L⁻¹ KCl, 2 mmol·L⁻¹ CaCl₂, 1.5 mmol·L⁻¹ MgCl₂, and 25 mmol·L⁻¹ HEPES, adjusted to pH = 7.4 with NaOH. The cells were clamped at -60 mV. Experiments were performed in at least triplicate at room temperature (25 °C).

2.4. Rapid ligand solution delivery

The cell-flow device used for rapid ligand solution delivery to membrane proteins at the cell surface has been described in detail [25]. To summarize, a U-shaped tube with a porthole of diameter of 150 μ m in the middle was connected to the inlet and outlet tubing, which were pumped by a Minipuls[®] 3 peristaltic pump (Glison, Inc.; Middleton, WI, USA). The solution delivery timing and length were automatically triggered and controlled. This device allowed the delivery of ligand solution to flow over the cell and exchange within milliseconds.

2.5. Curve fitting

GraphPad Prism Version 5.04 for Windows (GraphPad Software, Inc.; San Diego, CA, USA) was used to fit the inhibition curves of the receptors by LL and the dose-dependent responses of the GABA_AR in the absence and presence of 5 mmol·L⁻¹ LL. Agonist concentration–response relationships were fitted to the equation $I/I_{max} = 1/[1 + (EC_{50}/C_A)^{n_H}]$, where *I* and I_{max} represent the current at a given agonist concentration (C_A) and the maximal agonist-induced current, respectively. EC₅₀ is the half-maximal effective concentration and n_H is the Hill coefficient. PTZ inhibition-response relationships were fitted with the equation $I_A/I_0 = 1/[1 + (IC_{50}/C_{LL})^{n_H}]$, where I_A and I_0 are the current amplitudes in the presence and absence of LL, respectively. IC₅₀ is the half-maximal inhibitory concentration, and C_{LL} is the concentration of LL. Data were expressed as the mean ± standard error of mean (SEM).

3. Results

3.1. Dose-dependent inhibition by LL

LL at various concentrations was co-applied with 100 μ mol·L⁻¹ of GABA, a near-saturating concentration. Compared with the control current induced by 100 μ mol·L⁻¹ of GABA, it is clear that LL dose-dependently inhibited the $\alpha 1\beta 3\gamma 2L$ GABA_AR (Fig. 2(a)). Interestingly, LL also inhibited the $\alpha 3\beta 4$ nAChR with similar potency as on the GABA_AR (Fig. 2(b) versus Fig. 2(a)) when co-applied with carbamoylcholine, even though its efficacy seemed higher. The incomplete inhibition by LL on the GABA_AR is probably due to the solubility limit of LL in aqueous solution, as the highest concentration we were able to obtain was 50 mmol·L⁻¹. The whole-cell currents of the nAChR were induced by a near-saturating concentration of carbamoylcholine, which is a stable analog of the endogenous agonist acetylcholine.

The GABA dose–response curves in the absence and presence of 5 mmol·L⁻¹ LL showed that LL inhibited the whole-cell currents induced by the agonist GABA, while the agonist affinity was not changed (Fig. 3): The EC₅₀ values were $(36.2 \pm 7.9) \mu \text{mol·L}^{-1}$ and $(36.1 \pm 23.8) \mu \text{mol·L}^{-1}$ in the absence and presence of LL, respectively. Therefore, LL is a non-competitive inhibitor of the receptor.

Pentobarbital, an anticonvulsant drug used to treat seizures approved by the US Food and Drug Administration, potentiates $GABA_AR$ function at low concentrations (µmol·L⁻¹), but inhibits $GABA_AR$ function at high concentrations (mmol·L⁻¹) [26,27]. Therefore, we further tested the effect of LL on the $GABA_AR$ at concentrations of 25, 50, 75, 100, 200, 500, and 1000 µmol·L⁻¹. However, none of these low concentrations of LL exhibited any effect on the $GABA_AR$ (data not shown).

3.2. Mode of action of LL on GABA_AR

PTZ, also known as metrazol, causes convulsions and has been used in animal models to induce seizure. The PTZ-induced mouse seizure model (i.e., the scMET mouse model) has been used routinely to screen anticonvulsant drugs by programs such as the National Institutes of Health (NIH)'s Epilepsy Therapy Screening Program[†]. We wondered whether LL binds to the same site as PTZ. Our results showed that when LL was co-applied with

PTZ, the inhibition on GABA_AR was significantly increased in comparison with LL or PTZ alone (Fig. 4(a)). The PTZ binding site on GABA_AR is characterized as overlapped with the picrotoxin binding site [28,29]. Furthermore, the antagonistic effect of LL on the GABA_AR was reversible (Fig. 4(b)). Therefore, LL exerts its reversible allosteric GABA_AR modulation at a different site from the PTZ/picrotoxin site.

3.3. ME, EG, and citronellal are weak GABAAR and nAChR inhibitors

ME is a dose-dependent, direct agonist of the GABA_AR at concentrations greater than 100 μ mol·L⁻¹ (up to 10 mmol·L⁻¹), while sensitizing and potentiating GABA-induced currents at low concentrations of GABA (30 μ mol·L⁻¹) [30], which offers a possible explanation for its anticonvulsant activity. We further expanded on this to assess the antagonistic activity of ME at high doses (mmol·L⁻¹), considering that LL also inhibited GABA_AR at high doses. It was apparent that high doses (10 mmol·L⁻¹) of ME weakly antagonized the GABA_AR (Fig. 5). EG also had a similar effect at high doses (Fig. 5). Interestingly, both (*R*)-C and (*S*)-C weakly inhibited the α .3β4 nAChR (data not shown); however, (*R*)-C appeared to have no effect on the GABA_AR, whereas (*S*)-C had weak inhibitory activity on the GABA_AR (Fig. 5). In a word, ME, EG, and (*S*)-C are comparatively weak antagonists of the GABA_AR, and require very high doses to produce any change in GABA-induced currents.

4. Discussion

Based on the data available so far, it is difficult to make a conclusion on the primary target of EG and (R)-C/(S)-C. (R)-C/(S)-C has been shown to exert anticonvulsant and antinociceptive effects *in vivo*, which have been inferred to occur via GABA_AR modulation, albeit without a clear mechanism of action [31,32]. However, in the present *in vitro* study, EG and (S)-C had weak antagonistic effects on the GABA_AR and nAChR, suggesting that the primary target of action lay elsewhere. ME has been shown to be both a GABA_AR agonist at low concentrations and a positive allosteric modulator at moderate concentrations [30]; however, we have illustrated that it may be a weak GABA_AR antagonist at high doses, which suggests that the effects of ME are very complex.

The results of the present study demonstrate that LL is a concentration-dependent GABA_AR antagonist that modulates its activity outside of the PTZ/picrotoxin site on the GABA_AR. The inhibitory effect of LL on the GABA_AR observed in the present study disagrees with previous findings in which LL had anticonvulsant activities in cells and mouse models [8,33], and depressant effects on the CNS, sensory neurons [34], and even peripheral nerves [35]. The inhibitory effect of LL on the GABA_AR suggests neuronal excitability (e.g., seizure-like activity), which may provide a possible explanation for its use as an insecticide [5,6].

While this finding may seemingly contradict prior studies on LL's anticonvulsant and sedative effects, LL has been described to have multiple targets, including the *N*-methyl-*D*-aspartate (NMDA) receptor [11,33,36] and voltage-gated Na⁺ and Ca²⁺ channels [16,35]. LL has also been shown to inhibit acetylcholine release at the neuromuscular junction and the

[†]https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Epilepsy/ETSP.

kinetics of the miniature end-plate current decay [37]. Our results reveal that LL is a potent inhibitor of neuronal nAChR. When the homology between the muscle type and neuronal nAChR and the sharing of many allosteric modulators are considered [38], this finding comes as no surprise. At this time, further research is warranted to describe the primary molecular mechanism of action of LL. We hypothesize that the nAChR, NMDA receptors, and/or voltage-gated Na⁺ and Ca²⁺ channels may be the primary targets, as suggested by other studies [36], especially considering that NMDA receptors and voltage-gated Na⁺ and Ca²⁺ channels are targets of many other anticonvulsant drugs [39].

More importantly, the co-localization and crosstalk among those receptors in the CNS [40,41] make the interaction with small molecules different from the simple recombinant system used here. Mounting evidence has exemplified the co-localization and crosstalk among excitatory and inhibitory neurotransmitter receptors. For example, both potentiation and suppression of the GABA_AR function by NMDA receptor activation have been studied extensively, and vice versa [42–45]. The nAChR and GABA_AR are also co-localized in many areas of the brain, and activation of nAChR has been reported to block GABA-induced currents on hippocampal interneurons [46]. However, their interactions are not well understood.

Essential oils are composed of multiple monoterpenoids (including LL, ME, EG, and citronellal). It is reasonable to hypothesize that LL and other monoterpenoids modulate multiple different receptors and channels with varying potency to achieve synergistic effects [5]. It is also possible that monoterpenoids modulate the interplay among different neurotransmitter receptors. The observed mode of action of the monoterpenoids supports the use of essential oil components as sedatives, anticonvulsants, local anesthetics, and insecticides. The results warrant further research and development of essential oil components as human therapeutics and botanical insecticides, particularly the selectivity of monoterpenoids to various insect neuro-receptors.

Acknowledgements

This project was supported by grants from Bayer AG Crop Science (Grant4Targets 201701018), the National Center for Research Resources (5P20RR016467-11), and the National Institute of General Medical Sciences (P20GM103466) of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and Bayer AG Crop Science.

References

- Jeon S, Hur J, Jeong HJ, Koo BS, Pak SC. SuHeXiang Wan essential oil alleviates amyloid beta induced memory impairment through inhibition of tau protein phosphorylation in mice. Am J Chin Med 2011;39(5):917–32. [PubMed: 21905282]
- [2]. Agra MF, Baracho GS, Nurit K, Basílio IJ, Coelho VP. Medicinal and poisonous diversity of the flora of "Cariri Paraibano", Brazil. J Ethnopharmacol 2007;111 (2):383–95. [PubMed: 17236731]
- [3]. Lawless J. The encyclopedia of essential oils: the complete guide to the use of aromatic oils in aromatherapy, herbalism, health, and well being. San Francisco: Conari Press; 2013.
- [4]. Preedy VR, editor. Essential oils in food preservation, flavor and safety. Amsterdam: Academic Press; 2016.

- [5]. Chang CL, Cho IK, Li QX. Insecticidal activity of basil oil, trans-anethole, estragole, and linalool to adult fruit flies of *Ceratitis capitata, Bactrocera dorsalis*, and *Bactrocera cucurbitae*. J Econ Entomol 2009;102(1):203–9. [PubMed: 19253638]
- [6]. Jankowska M, Rogalska J, Wyszkowska J, Stankiewicz M. Molecular targets for components of essential oils in the insect nervous system–a review. Molecules 2017;23(1):34. [PubMed: 29295521]
- [7]. Letizia CS, Cocchiara J, Lalko J, Api AM. Fragrance material review on linalool. Food Chem Toxicol 2003;41(7):943–64. [PubMed: 12804650]
- [8]. de Almeida RN, Agra Mde F, Maior FN, de Sousa DP. Essential oils and their constituents: anticonvulsant activity. Molecules 2011;16(3):2726–42. [PubMed: 21441872]
- [9]. Nascimento SS, Araújo AA, Brito RG, Serafini MR, Menezes PP, DeSantana JM, et al. Cyclodextrin-complexed *Ocimum basilicum* leaves essential oil increases Fos protein expression in the central nervous system and produce an antihyperalgesic effect in animal models for fibromyalgia. Int J Mol Sci 2015;16(1):547–63.
- [10]. De Sousa DP, Nóbrega FF, Santos CC, de Almeida RN. Anticonvulsant activity of the linalool enantiomers and racemate: investigation of chiral influence. Nat Prod Commun 2010;5(12):1847–51. [PubMed: 21299105]
- [11]. Batista PA, Werner MF, Oliveira EC, Burgos L, Pereira P, Brum LF, et al. Evidence for the involvement of ionotropic glutamatergic receptors on the antinociceptive effect of (–)-linalool in mice. Neurosci Lett 2008;440 (3):299–303. [PubMed: 18579302]
- [12]. Hirai M, Ito M. Sedative effects of the essential oil and headspace air of *Ocimum basilicum* by inhalation in mice. J Nat Med 2019;73(1):283–8. [PubMed: 30343352]
- [13]. Melo FH, Moura BA, de Sousa DP, de Vasconcelos SM, Macedo DS, Fonteles MM, et al. Antidepressant-like effect of carvacrol (5-isopropyl-2-methylphenol) in mice: involvement of dopaminergic system. Fundam Clin Pharmacol 2011;25(3):362–7. [PubMed: 20608992]
- [14]. Melo FH, Venâncio ET, de Sousa DP, de França Fonteles MM, de Vasconcelos SM, Viana GS, et al. Anxiolytic-like effect of carvacrol (5-isopropyl-2-methylphenol) in mice: involvement with GABAergic transmission. Fundam Clin Pharmacol 2010;24(4):437–43. [PubMed: 19909350]
- [15]. Peana AT, De Montis MG, Sechi S, Sircana G, D'Aquila PS, Pippia P. Effects of (-)-linalool in the acute hyperalgesia induced by carrageenan, *L*-glutamate and prostaglandin E₂. Eur J Pharmacol 2004;497(3):279–84. [PubMed: 15336945]
- [16]. Malcolm BJ, Tallian K. Essential oil of lavender in anxiety disorders: ready for prime time? Ment Health Clin 2018;7(4):147–55. [PubMed: 29955514]
- [17]. Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABA_A receptors. Seizure 2013;22(8):589–600. [PubMed: 23683707]
- [18]. Kami ski K, Obniska J, Chlebek I, Liana P, P kala E. Synthesis and biological properties of new *N*-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V Eur J Med Chem 2013;66:12–21. [PubMed: 23777899]
- [19]. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Vallés AS, et al. The anticonvulsive drug lamotrigine blocks neuronal α4β2 nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2010;335(2):401–8. [PubMed: 20688974]
- [20]. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na⁺ channels and with native Na⁺ channels in rat hippocampal neurones. Pflugers Arch 1995;430 (3):437–46. [PubMed: 7491269]
- [21]. Li QX, Chang CL. Basil (*Ocimum basilicum* L.) oils. In: Preedy VR, editor. Essential oils in food preservation, flavor and safety Amsterdam: Academic Press; 2016. p. 231–8.
- [22]. Wong G, Sei Y, Skolnick P. Stable expression of type I gamma-aminobutyric acid-A/ benzodiazepine receptors in a transfected cell line. Mol Pharmacol 1992;42(6):996–1003.
 [PubMed: 1336119]
- [23]. Davies PA, Hoffmann EB, Carlisle HJ, Tyndale RF, Hales TG. The influence of an endogenous β3 subunit on recombinant GABA_A receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. Neuropharmacology 2000;39(4):611–20. [PubMed: 10728882]

- [24]. Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ. Rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. Mol Pharmacol 1998;54(2):322–33. [PubMed: 9687574]
- [25]. Udgaonkar JB, Hess GP. Chemical kinetic measurements of a mammalian acetylcholine receptor by a fast-reaction technique. Proc Natl Acad Sci USA 1987;84(24):8758–62. [PubMed: 2447583]
- [26]. Akk G, Steinbach JH. Activation and block of recombinant GABA_A receptors by pentobarbitone: a single-channel study. Br J Pharmacol 2000;130 (2):249–58. [PubMed: 10807661]
- [27]. Steinbach JH, Akk G. Modulation of GABA_A receptor channel gating by pentobarbital. J Physiol 2001;537(Pt 3):715–33. [PubMed: 11744750]
- [28]. Dibas MI, Dillon GH. The central nervous system convulsant pentylenetetrazole stimulates gamma-aminobutyric acid (GABA)-activated current in picrotoxin-resistant GABA_A receptors in HEK293 cells. Neurosci Lett 2000;285(3):193–6. [PubMed: 10806319]
- [29]. Gurley D, Amin J, Ross PC, Weiss DS, White G. Point mutations in the M2 region of the alpha, beta, or gamma subunit of the GABA_A channel that abolish block by picrotoxin. Receptor Channel 1995;3(1):13–20.
- [30]. Ding J, Huang C, Peng Z, Xie Y, Deng S, Nie YZ, et al. Electrophysiological characterization of methyleugenol: a novel agonist of GABA_A receptors. ACS Chem Neurosci 2014;5(9):803–11. [PubMed: 24980777]
- [31]. Melo MS, Sena LC, Barreto FJN, Bonjardim LR, Almeida JRGS, Lima JT, et al. Antinociceptive effect of citronellal in mice. Pharm Biol 2010;48(4):411–6. [PubMed: 20645719]
- [32]. de Sousa DP, Gonçalves JCR, Quintans-Júnior L, Cruz JS, Araújo DA, de Almeida RN. Study of anticonvulsant effect of citronellol, a monoterpene alcohol, in rodents. Neurosci Lett 2006;401(3):231–5. [PubMed: 16650577]
- [33]. Elisabetsky E, Brum LFS, Souza DO. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine 1999;6(2):107–13. [PubMed: 10374249]
- [34]. Narusuye K, Kawai F, Matsuzaki K, Miyachi E. Linalool suppresses voltage-gated currents in sensory neurons and cerebellar Purkinje cells. J Neural Transm (Vienna) 2005;112(2):193–203. [PubMed: 15365786]
- [35]. Leal-Cardoso JH, da Silva-Alves KS, Ferreira-da-Silva FW, dos Santos-Nascimento T, Joca HC, de Macedo FH, et al. Linalool blocks excitability in peripheral nerves and voltage-dependent Na⁺ current in dissociated dorsal root ganglia neurons. Eur J Pharmacol 2010;645(1–3):86–93. [PubMed: 20655301]
- [36]. Brum LF, Elisabetsky E, Souza D. Effects of linalool on [³H] MK801 and [³H] muscimol binding in mouse cortical membranes. Phytother Res 2001;15 (5):422–5. [PubMed: 11507735]
- [37]. Re L, Barocci S, Sonnino S, Mencarelli A, Vivani C, Paolucci G, et al. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res 2000;42(2):177–82. [PubMed: 10887049]
- [38]. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89 (1):73–120. [PubMed: 19126755]
- [39]. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5(7):553–64. [PubMed: 15208697]
- [40]. Cong D, Tang Z, Li L, Huang Y, Wang J, Chen L. Cross-talk between NMDA and GABA_A receptors in cultured neurons of the rat inferior colliculus. Sci China Life Sci 2011;54(6):560–6. [PubMed: 21706417]
- [41]. Chisari M, Zorumski CF, Mennerick S. Cross talk between synaptic receptors mediates NMDAinduced suppression of inhibition. J Neurophysiol 2012;107 (9):2532–40. [PubMed: 22279196]
- [42]. Chen QX, Stelzer A, Kay AR, Wong RK. GABA_A receptor function is regulated by phosphorylation in acutely dissociated guinea-pig hippocampal neurones. J Physiol 1990;420(1):207–21. [PubMed: 2157838]
- [43]. Chen QX, Wong RK. Suppression of GABA_A receptor responses by NMDA application in hippocampal neurones acutely isolated from the adult guinea-pig. J Physiol 1995;482(Pt 2):353– 62. [PubMed: 7714826]

- [44]. Zhu WJ, Vicini S, Harris BT, Grayson DR. NMDA-mediated modulation of gamma-aminobutyric acid type A receptor function in cerebellar granule neurons. J Neurosci 1995;15(11):7692–701. [PubMed: 7472520]
- [45]. Stelzer A, Slater NT, ten Bruggencate G. Activation of NMDA receptors blocks GABAergic inhibition in an *in vitro* model of epilepsy. Nature 1987;326 (6114):698–701. [PubMed: 2882427]
- [46]. Zhang J, Berg DK. Reversible inhibition of GABA_A receptors by α7-containing nicotinic receptors on the vertebrate postsynaptic neurons. J Physiol 2007;579 (Pt 3):753–63. [PubMed: 17204496]



Fig. 1. Structures of (a) (–)-LL, (b) ME, (c) EG, and (d) citronellal.



Fig. 2.

Dose-dependent inhibition of LL on the whole-cell currents of the (a) $\alpha 1\beta 3\gamma 2L \text{ GABA}_A R$ induced by 100 µmol·L⁻¹ GABA and (b) $\alpha 3\beta 4$ nAChR induced by 3 mmol·L⁻¹ carbamoylcholine. Rat $\alpha 1\beta 3\gamma 2L$ GABA_AR was stably expressed in the WSS-1 cells, while the rat $\alpha 3\beta 4$ nAChR subtype was stably expressed in the KX $\alpha 3\beta 4R2$ cell line. The maximal inhibition by LL on the GABA_AR was 44% of the control and 13% on the nAChR. Carbamoylcholine, a stable analog of acetylcholine, was used as a control for the whole-cell current recordings of the nAChR.



Fig. 3.

GABA dose–response curves in the absence (black) and presence (blue) of 5 mmol·L⁻¹ LL in WSS-1 cells that expressed the rat $\alpha 1\beta 3\gamma 2L$ GABA_A receptor. The EC₅₀ values were (36.2 ± 7.9) µmol·L⁻¹ and (36.1 ± 23.8) µmol·L⁻¹ in the absence and presence of LL, respectively. *C*_{GABA}: the concentration of GABA.



Fig. 4.

(a) Significant increase in inhibition on rat $\alpha 1\beta 3\gamma 2L$ GABA_AR by the co-application of LL with PTZ relative to LL or PTZ alone. (b) Representative whole-cell current recording induced by 100 µmol·L⁻¹ GABA (control, black), followed by 5 mmol·L⁻¹ LL + 100 µmol·L⁻¹ GABA (red) with subsequent return to the original control current with 100 µmol·L⁻¹ GABA only (blue) 1 min after treatment.



Fig.5.

Co-applications of 10 mmol·L⁻¹ ME with 10 μ mol·L⁻¹ GABA and 100 μ mol·L⁻¹ GABA, respectively, weakly inhibited GABAAR functions. Co-applications of 10 mmol·L⁻¹ EG with 10 μ mol·L⁻¹ GABA inhibited GABA_AR functions. 5 mmol·L⁻¹ (*R*)-C did not inhibit GABA_AR-induced currents when co-applied with 40 μ mol·L⁻¹ GABA; and 5 mmol·L⁻¹ (S)-C in the presence of 40 μ mol·L⁻¹ GABA weakly inhibited the GABA_AR.